| Literature DB >> 34729140 |
Ting Yang1, Jin Zhang2, Bing Wang2, Wen Zhang2, Min Xu2, Shuangyuan Yang1, Hui Liu3.
Abstract
BACKGROUND AND AIMS: Tinnitus is one of the most common otological symptoms that patients experience, and it can be debilitating. No effective drug treatments are available for tinnitus, although considerable research investigating its mechanisms and possible treatments is underway. Electrical stimulation has been considered a promising and well-tolerated therapeutic strategy for tinnitus. This meta-analysis study was aimed to investigate the efficacy, safety and tolerability of electrical stimulation in patients with tinnitus.Entities:
Keywords: electrical stimulation; meta-analysis; tinnitus; transcranial direct current stimulation; transcutaneous electrical nerve stimulation
Year: 2021 PMID: 34729140 PMCID: PMC8442493 DOI: 10.1177/20406223211041069
Source DB: PubMed Journal: Ther Adv Chronic Dis ISSN: 2040-6223 Impact factor: 5.091
Figure 1.Flow diagram of the selection of the included studies.
Characteristics of the included studies and participants.
| Author | Country | Types of tinnitus | Sex (M/F) | Age | Sample size | Tinnitus duration | Laterality of tinnitus (R/L/B) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | C | T | C | T | C | T | C | |||||
| Wu and colleagues[ | China | Idiopathic tinnitus | 19/15 | 16/18 | 37.25 ± 12.49 | 40.73 ± 10.66 | 34 | 34 | 4.29 ± 2.15 M | 4.97 ± 2.39 M | NA | |
| Souza and colleagues[ | Brazil | Individuals free from any neurological and/or organic comorbidities | 2/10 | 6/6 | 44.58 ± 16.20 | 55.50 ± 9.72 | 12 | 12 | 24 (12–33) M | 30 (6.75–126) M | 4/6/2 | 3/4/5 |
| Tutar and colleagues[ | Turkey | Subjective tinnitus | 22/38 | 41.17 ± 10.75 | 20 | 20 | 31 ± 49 M | NA | ||||
| Li and colleagues[ | China | Acute tinnitus | 14/9 | 17/6 | 46.8 ± 11.6 | 48.4 ± 14.1 | 23 | 23 | 3.7 ± 1.4 M | 4.0 ± 1.6 M | 3/5/15 | 4/7/12 |
| Yadollahpour and colleagues[ | Iran | Intractable chronic tinnitus | 11/14 | 7/8 | 47.52 ± 7.51 | 47.67 ± 7.96 | 25 | 15 | 7.48 ± 3.99 | 7.60 ± 3.60 | 8/4/13 | 3/5/7 |
| Yadollahpour and colleagues[ | Iran | Chronic intractable tinnitus | 11/14 | 8/9 | 46.68 ± 6.87 | 47.53 ± 7.56 | 25 | 17 | 7.8 ± 2.84 y | 8.11 ± 2.8 y | 11/4/10 | 6/5/6 |
| Cavalcanti[ | Brazil | Chronic tinnitus | 9/9 | 54.72 (45–70) | 9 | 9 | 12.86 (1–30) M | 9 (Bilateral) | ||||
| Pal and colleagues[ | Switzerland | Chronic (⩾1 year) nonpulsatile subjective tinnitus | 12/9 | 12/9 | 51.6 ± 12.2 | 48 ± 9.9 | 21 | 21 | 63.1 ± 64.9 M | 71 ± 102.3 M | 0/0/21 | 0/0/21 |
| Forogh and colleagues[ | Iran | Chronic tinnitus | 7/4 | 7/4 | 49.81 ± 4.14 | 46.63 ± 5.26 | 11 | 11 | 9 ± 3.67 y | 6.54 ± 1.44 y | 3/1/7 | 0/3/8 |
| Lee and colleagues[ | Korea | Chronic, subjective tinnitus | 26/9 | 13/7 | 46.6 ± 13.9 | 45.6 ± 11.5 | 45 | 20 | 24.44 ± 19.79 M | 20/25/0 | 8/12/0 | |
| Shekhawat and colleagues[ | New Zealand | Chronic tinnitus (more than 2 years) | 18/2 | 18/2 | 58.5 ± 6.4 | 59.85 ± 9.6 | 20 | 20 | 19.78 y | 16.55 y | 18/1/1 | 16/3/1 |
B, bilateral; C, control group; F, female; L, left side; M, male; M, month; NA, not available; R, right side; T, treatment group; y, year.
Data are presented as mean ± standard deviation.
Details of the treatment condition.
| Author | Type of stimulation treatment | Stimulus frequency | stimulus intensity | Location of stimulation | Treatment duration | Protocol (number of treatment) | Adjuvant therapy | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | C | T | C | T | C | T | C | T | C | T | C | ||
| Wu and colleagues[ | Concha auriculae electroacupuncture | 4–20 Hz | - | 4–10 mA | - | Cavity of auricular concha [auricular branch of the vagus nerve (ABVN)] | Ear marginal scapha of the left ear | 30 min | 3 times for 1 week | Oral mecobalamin 0.2 mg Tid for 12 weeks | |||
| Souza and colleagues[ | Transcranial direct current stimulation | Delta (0.5–3.5 Hz), theta (4–7.5 Hz), alpha (8–12 Hz), beta (12.5–30 Hz) and gamma (30.5–60 Hz) | - | 2 mA | - | PFC + LTA | 20 min | 5 consecutive days | NA | ||||
| Tutar and colleagues[ | Transcutaneous electrical nerve stimulation | 200 Hz | - | 10–30 mA | - | Cymba conchae where there is rich ABVN | 30 min | 10 sessions in 1 month, maximum of 4 days between each session | NA | ||||
| Li and colleagues[ | Transcutaneous electrical nerve stimulation | 2/100 Hz | - | NA | A pair of electrodes was placed on the left and right C2 nerves dermatomes | 30 min | 3 times weekly for a total of 4 weeks | Parenteral intramuscular therapy of 1-ml vitamin B12 (2500 mcg) weekly for a total of 4 weeks | |||||
| Yadollahpour and colleagues[ | Transcranial direct current stimulation | NA | 2 mA | - | The anode was placed over left AC (halfway T3–F7) and cathode over right AC (halfway T4–F8) with 35-cm2 electrodes. | 20 min | Over 5 consecutive days per week for 2 consecutive weeks (total, 10 sessions) | NA | |||||
| Yadollahpour and colleagues[ | Transcranial direct current stimulation | NA | 2 mA | - | Anode was placed over the right DLPFC (F4), and the cathode over the left DLPFC (F3) | 20 min | Over 5 consecutive days per week for 2 consecutive weeks (total, 10 sessions) | NA | |||||
| Cavalcanti[ | Transcranial direct current stimulation | NA | 2 mA | - | PFC | 20 min (10 s ramp-in and ramp-out each) | A ramp-in period of 10 s, after which the current was turned off for the remainder of the session | 5 consecutive daily sessions | NA | ||||
| Pal and colleagues[ | Transcranial direct current stimulation | NA | 2 mA | 1 mA | PFC | 20 min | For 90 s in a ramp-like fashion | 5 days (1× session/day: Monday–Friday) | NA | ||||
| Forogh and colleagues[ | Transcranial direct current stimulation | NA | 2 mA | - | LTA | 20 min | 4 s after the initial ramp-up, the current was directly ramped down to 0 | 5 sessions of stimulation in 5 consecutive days. | NA | ||||
| Lee and colleagues[ | Transcutaneous electrical stimulation | 50 Hz | - | 15 mA | - | Five sites that on the auricle of the ear with tinnitus. | 30 s for each point | Twice a week for a total of 8 therapy sessions over 4 weeks | No other treatments for tinnitus including medications or psychotherapy were administered | ||||
| Shekhawat and colleagues[ | Transcranial direct current stimulation | NA | 2 mA | - | LTA | 20 min | 5 consecutive sessions with 24-h gap | All the participants were fitted bilaterally with GN ReSound Live 571 open-fit hearing aids on the day following the final brain stimulation session | |||||
AC, auditory cortex; C, control group; DLPFC, dorsolateral prefrontal cortex; LTA, left temporoparietal area; NA, not available; PFC, prefrontal cortex; T, treatment group.
Summary of the treatment outcomes.
| Author | Group | Questionnaire | Score, mean (SD) | Jadad score | Follow-up period | Side effects | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Poststimulation | Difference | ||||||||
| Wu and colleagues[ | T | THI | 49.76 (4.80) | 28.09 (3.64) | −21.67 (4.34) | 3 | <0.05 | 12 weeks after postintervention | NA | |
| C | 48.56 (4.20) | 29.19 (1.91) | −19.37 (3.64) | |||||||
| T | SDS | 45.34 (2.72) | 43.47 (3.13) | −1.87 (3.64) | ||||||
| C | 44.91 (1.81) | 42.22 (1.60) | −2.69 (1.71) | |||||||
| T | SAS | 48.89 (4.28) | 41.96 (3.07) | −6.93 (3.82) | ||||||
| C | 51.20 (1.81) | 45.63 (2.13) | −5.57 (1.99) | |||||||
| T | SF-36 | Physical | 50.40 (3.87) | 66.33 (5.56) | 15.93 (4.94) | |||||
| C | 50.04 (4.71) | 62.26 (5.08) | 12.22 (4.91) | |||||||
| T | Social function | 50.84 (3.98) | 67.96 (6.19) | 17.12 (5.43) | ||||||
| C | 51.43 (5.92) | 65.01 (5.13) | 13.58 (5.57) | |||||||
| T | Physical function | 49.64 (4.65) | 71.29 (6.46) | 21.65 (5.50) | ||||||
| C | 49.27 (5.49) | 63.88 (5.12) | 14.61 (5.31) | |||||||
| T | Emotion | 51.48 (3.96) | 75.3 (7.11) | 23.82 (6.17) | ||||||
| C | 49.49 (5.51) | 71.63 (5.33) | 22.14 (5.42) | |||||||
| T | Somatoform pain | 51.41 (5.04) | 74.25 (5.57) | 19.67 (4.82) | ||||||
| C | 50.67 (5.49) | 70.34 (3.54) | 11.31 (4.33) | |||||||
| T | Metal health | 49.83 (2.92) | 61.14 (4.97) | 7.91 (8.51) | ||||||
| C | 50.39 (5.32) | 58.30 (4.05) | 12.35 (4.54) | |||||||
| T | General health | 49.98 (4.05) | 62.33 (4.90) | 12.35 (4.54) | ||||||
| C | 50.69 (5.54) | 55.96 (4.96) | 5.27 (5.27) | |||||||
| T | Vitality | 49.98 (6.78) | 71.75 (5.45) | 21.77 (6.22) | ||||||
| C | 51.08 (3.74) | 68.81 (5.85) | 17.73 (5.13) | |||||||
| Souza and colleagues[ | T | THI | 52 (7.9) | 35 (5.1) | −17 (6.94) | 4 | <0.0001 | 5 days after postintervention | NA | |
| C | 44 (5.8) | 42 (7.3) | −2 (6.68) | |||||||
| T | VAS | 7.5 (0.4) | 7 (0.6) | −0.5 (0.53) | ||||||
| C | 7.5 (0.6) | 4.2 (0.8) | −3.3 (0.72) | |||||||
| Tutar and colleagues[ | T | DASS | Depression | 13.10 (7.80) | 4.35 (2.54) | −8.75 (7.11) | 4 | <0.05 | 4 weeks after postintervention | NA |
| C | 13.10 (5.82) | 9.45 (5.83) | −3.65 (3.44) | |||||||
| T | Anxiety | 13.50 (6.08) | 4.40 (3.09) | −9.10 (6.11) | ||||||
| C | 13.50 (4.99) | 10.30 (5.56) | −3.20 (2.98) | |||||||
| T | Stress | 15.95 (6.04) | 6.64 (3.32) | −9.50 (5.48) | ||||||
| C | 15.85 (6.23) | 12.45 (5.62) | −3.40 (3.58) | |||||||
| T | THI | 33.05 (21.09) | 8.60 (4.89) | −24.45 (19.12) | ||||||
| C | 37.95 (20.96) | 28.65 (14.99) | −9.30 (18.7) | |||||||
| Li and colleagues[ | T | THI | 31.8 (12.6) | NA | −11.6 (11.24) | 6 | <0.01 | 4 weeks after postintervention | No adverse events related to the verum TENS or sham TENS intervention occurred in either group | |
| C | 30.2 (14.3) | −2.9 (2.79) | ||||||||
| T | TSS | 22.8 (7.7) | −9.3 (9.01) | |||||||
| C | 21.1 (6.9) | −3.1 (3.0) | ||||||||
| T | TQ | 20.1 (9.5) | −13.8 (13.37) | |||||||
| C | 19.3 (8.4) | −3.5 (3.39) | ||||||||
| T | SF-12 | Physical | 77.6 (16.2) | 11.3 (10.93) | ||||||
| C | 79.3 (17.0) | 2.5 (2.41) | ||||||||
| T | Mental | 80.1 (15.4) | 12.6 (12.2) | |||||||
| C | 81.6 (14.4) | 3.0 (2.91) | ||||||||
| Yadollahpour and colleagues[ | T | THI | 71.28 (10.57) | 46.4 (15.36) | −24.88 (13.61) | 4 | NA | 1 h, 1 week and 1 month after postintervention | Itching, tingling, scalp pain, burning, pinching, fatigue, headache, skin irritation, discomfort | |
| C | 71.6 (9.57) | 66.73 (14.3) | −4.87 (12.62) | |||||||
| T | VAS | Loudness | 7.36 (0.81) | 5.6 (1.78) | −1.76 (0.97) | |||||
| C | 7.46 (0.92) | 6.8 (1.52) | −0.67 (0.61) | |||||||
| T | Distress | 7.68 (0.56) | 5.92 (1.25) | −1.76 (0.70) | ||||||
| C | 7.07 (1.22) | 7.67 (0.62) | −0.6 (0.61) | |||||||
| Yadollahpour and colleagues[ | T | THI | 69.88 (9.45) | 47.24 (12.45) | −22.75 (11.25) | 4 | NA | 1 h, 1 week and 1 month after postintervention | NA | |
| C | 69.82 (9.45) | 61.94 (13.51) | −7.88 (12.01) | |||||||
| T | VAS | Loudness | 7.44 (0.96) | 5.88 (1.79) | −1.56 (0.83) | |||||
| C | 7.58 (0.94) | 7.18 (1.24) | −0.41 (0.29) | |||||||
| T | Distress | 7.72 (0.61) | 6.48 (1.19) | −1.24 (0.58) | ||||||
| C | 7.65 (0.61) | 7.17 (1.29) | −0.47 (0.68) | |||||||
| Cavalcanti[ | T | THI | 48.0 (26.0) | 46.0 (28.0) | −2.0 (27.06) | 3 | NA | 5 days after postintervention | With no untoward effects | |
| C | 52.0 (25.0) | 49.0 (25.0) | −3.0 (25.0) | |||||||
| T | VAS | 7 (2.4) | 7.3 (1.6) | 0.3 (2.12) | ||||||
| C | 7.3 (1.8) | 0.3 (2.16) | ||||||||
| Pal and colleagues[ | T | THI | 46.7 (20.0) | 42.1 (20.3) | −4.6 (20.15) | 4 | NA | 5 days after postintervention; 1 month after last intervention; 3 months after last intervention | No other side effects were reported. All patients experienced occasional ‘tingling’, which was most commonly of short duration, with no pain or discomfort | |
| C | 46.4 (18.2) | 45.8 (18.7) | −0.6 (18.46) | |||||||
| T | VAS | Intensity | 57.0 (20.3) | 57.2 (18.6) | 0.2 (19.51) | |||||
| C | 59.4 (19.8) | 59.4 (18.2) | 0.0 (19.05) | |||||||
| T | Distress | 55.2 (25.8) | 48.2 (21.7) | −7.0 (24.01) | ||||||
| C | 54.2 (25.4) | 46.4 (24.5) | −7.8 (24.96) | |||||||
| T | STSS | 10.6 (2.6) | 10.6 (2.6) | 0.0 (2.6) | ||||||
| C | 10.1 (1.7) | 10.3 (2.2) | 0.2 (2.0) | |||||||
| T | CGI | NA | 4.0 (0.7) | NA | ||||||
| C | 4.1 (0.6) | |||||||||
| T | HAD | 14.6 (7.6) | 12.4 (7.3) | −2.2 (7.45) | ||||||
| C | 15.1 (6.3) | 15.3 (6.9) | 0.2 (6.62) | |||||||
| Forogh and colleagues[ | T | THI | 58.6 (28.1) | 55.8 (23.2) | −2.8 (26.0) | 6 | 0.729 | After fifth session; 2 weeks after stimulation | NA | |
| C | 53.7 (20.0) | 53.4 (30.9) | −0.3 (27.14) | |||||||
| T | VAS | Loudness | 5.3 (2.6) | 5.1 (2.5) | −0.2 (2.55) | 0.964 | ||||
| C | 5.2 (2.5) | 4.8 (2.8) | −0.4 (2.66) | |||||||
| T | Distress | 5.6 (2.5) | 5.0 (2.2) | −0.6 (2.36) | 0.339 | |||||
| C | 4.7 (2.3) | 4.2 (2.4) | −0.5 (2.35) | |||||||
| Lee and colleagues[ | T | THI | 49.4 (9.9) | 42.8 (8.7) | −6.6 (9.36) | 3 | <0.05 | After 4-week sessions | Mild side effects were seen in eight patients including four patients with dizziness, three patients with headache and one patient with facial numbness. However, side effects dissipated after cessation of treatment | |
| C | 44.5 (6.5) | 45.2 (7.9) | −0.7 (7.30) | >0.05 | ||||||
| T | VAS | Duration | 6.9 (1.6) | 5.6 (2.1) | −1.3 (1.9) | <0.05 | ||||
| C | 6.5 (1.2) | 6.1 (1.5) | −0.4 (1.37) | >0.05 | ||||||
| T | Loudness | 6.7 (1.7) | 5.8 (1.9) | −0.9 (1.81) | <0.05 | |||||
| C | 6.2 (1.9) | 5.6 (1.6) | −0.6 (1.77) | >0.05 | ||||||
| T | Annoyance | 6.7 (1.5) | 5.4 (2.2) | −1.3 (1.95) | <0.05 | |||||
| C | 6.5 (1.7) | 5.7 (1.2) | −0.8 (1.51) | >0.05 | ||||||
| T | Difficulty in activities of daily life | 6.8 (1.9) | 5.4 (1.9) | −1.4 (1.9) | <0.05 | |||||
| C | 6.6 (1.7) | 6.5 (1.3) | −0.1 (1.54) | >0.05 | ||||||
| Shekhawat and colleagues[ | T | TFI | −2.5 (2.5) | −6 (3) | −3.5 (2.78) | 3 | >0.05 | During 5 stimulation sessions; before hearing aid fitting; 3 months; 6 months | NA | |
| C | −3 (3) | −3 (3) | ||||||||
| T | VAS | Loudness | NA | −0.33 (0.58) | ||||||
| C | −0.06 (0.89) | |||||||||
C, control group; CGI, Clinical Global Impression Scale; DASS, Depression Anxiety Stress Scales; HAD, Hospital Anxiety and Depression scale; LTA, left temporoparietal area; NA, not available; PFC, prefrontal cortex; SAS, Self-Rating Anxiety Scale; SDS, Self-Rating Depression Scale; STSS, Subjective Tinnitus Severity Scale; T, treatment group; TENS, transcutaneous electric nerve stimulation; TFI, Tinnitus Functional Index; THI, Tinnitus Handicap Inventory; TQ, tinnitus questionnaire; TSS, Tinnitus Severity Scale; VAS, visual analogue scale; SF, social function.
Data are presented as mean (standard deviation).
Figure 2.Risk of bias graph.
Figure 3.Risk of bias summary.
Figure 4.Analysis comparing electrical stimulation versus sham stimulation for the THI change scale score in tinnitus patients.
CI, confidence interval; IV, inverse variance; THI, Tinnitus Handicap Inventory.
Figure 5.Subgroup analysis of the THI change scale score comparing electrical stimulation with sham stimulation by follow-up period.
CI, confidence interval; IV, inverse variance; THI, Tinnitus Handicap Inventory.
Figure 6.Subgroup analysis of the THI change scale score comparing electrical stimulation with sham stimulation by tinnitus duration.
CI, confidence interval; IV, inverse variance; THI, Tinnitus Handicap Inventory.
Figure 7.Subgroup analysis of the THI change scale score comparing electrical stimulation with sham stimulation by stimulation intensity.
CI, confidence interval; IV, inverse variance; THI, Tinnitus Handicap Inventory.
Figure 8.Subgroup analysis of the THI change scale score comparing TENS with sham stimulation by stimulation areas.
CI, confidence interval; IV, inverse variance; TENS, transcutaneous electric nerve stimulation; THI, Tinnitus Handicap Inventory.
Figure 9.Subgroup analysis of the THI change scale score comparing tDCS with sham stimulation by stimulation areas.
CI, confidence interval; IV, inverse variance; LTA, left temporoparietal area; PFC, prefrontal cortex; tDCS, transcranial direct current stimulation; THI, Tinnitus Handicap Inventory.
Figure 10.Analysis comparing electrical stimulation versus sham stimulation for the VAS loudness change scale score in tinnitus patients.
CI, confidence interval; IV, inverse variance; VAS, visual analogue scale.
Figure 11.Analysis comparing electrical stimulation versus sham stimulation for the VAS distress change scale score in tinnitus patients.
CI, confidence interval; IV, inverse variance; VAS, visual analogue scale.
Figure 12.Sensitivity analysis of included studies for THI change scores.
CI, confidence interval; THI, Tinnitus Handicap Inventory.
Figure 13.Funnel plot of included studies for THI change scores.
THI, Tinnitus Handicap Inventory.
Figure 14.Egger’s test of included studies.